293 related articles for article (PubMed ID: 37760542)
1. Immunotherapy and Liver Transplantation: A Narrative Review of Basic and Clinical Data.
Wassmer CH; El Hajji S; Papazarkadas X; Compagnon P; Tabrizian P; Lacotte S; Toso C
Cancers (Basel); 2023 Sep; 15(18):. PubMed ID: 37760542
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy and transplantation for hepatocellular carcinoma.
Tabrizian P; Abdelrahim M; Schwartz M
J Hepatol; 2024 May; 80(5):822-825. PubMed ID: 38253289
[TBL] [Abstract][Full Text] [Related]
3. Liver Transplantation for Hepatocellular Carcinoma after Downstaging or Bridging Therapy with Immune Checkpoint Inhibitors.
Gao Q; Anwar IJ; Abraham N; Barbas AS
Cancers (Basel); 2021 Dec; 13(24):. PubMed ID: 34944927
[TBL] [Abstract][Full Text] [Related]
4. Optimizing the Safe Washout Period for Liver Transplantation Following Immune Checkpoint Inhibitors with Atezolizumab, Nivolumab, or Pembrolizumab.
Kuo FC; Chen CY; Lin NC; Liu C; Hsia CY; Loong CC
Transplant Proc; 2023 May; 55(4):878-883. PubMed ID: 37127513
[TBL] [Abstract][Full Text] [Related]
5. Immune checkpoint inhibitors in liver transplant: a case series.
Rudolph M; Shah SA; Quillin R; Lemon K; Olowokure O; Latif T; Sohal D
J Gastrointest Oncol; 2023 Apr; 14(2):1141-1148. PubMed ID: 37201081
[TBL] [Abstract][Full Text] [Related]
6. Rescue liver re-transplantation after graft loss due to severe rejection in the setting of pre-transplant nivolumab therapy.
Dehghan Y; Schnickel GT; Hosseini M; Burgoyne AM; Ajmera VH; Morris GP; Mendler MH; Parekh JR; Abushamat F; Vodkin I; Kono Y
Clin J Gastroenterol; 2021 Dec; 14(6):1718-1724. PubMed ID: 34643885
[TBL] [Abstract][Full Text] [Related]
7. The Safety and Efficacy of Checkpoint Inhibitors in Transplant Recipients: A Case Series and Systematic Review of Literature.
Kumar V; Shinagare AB; Rennke HG; Ghai S; Lorch JH; Ott PA; Rahma OE
Oncologist; 2020 Jun; 25(6):505-514. PubMed ID: 32043699
[TBL] [Abstract][Full Text] [Related]
8. Trial watch: immunotherapeutic strategies on the horizon for hepatocellular carcinoma.
Koh B; Tan DJH; Lim WH; Wong JSL; Ng CH; Chan KE; Wang M; Yong WP; Dan YY; Wang LZ; Tan N; Muthiah M; Kow A; Syn NL; Huang DQ; Yau T
Oncoimmunology; 2023; 12(1):2214478. PubMed ID: 37284696
[TBL] [Abstract][Full Text] [Related]
9. Understanding immune perspectives and options for the use of checkpoint immunotherapy in HCC post liver transplant.
Anugwom CM; Leventhal TM; Debes JD
Hepatoma Res; 2022; 8():. PubMed ID: 35693455
[TBL] [Abstract][Full Text] [Related]
10. Hepatocellular Carcinoma: The Role of Immunotherapy and Transplantation in the Era of Transplant Oncology.
Alghamdi S; Al-Hamoudi W
Cancers (Basel); 2023 Oct; 15(21):. PubMed ID: 37958291
[TBL] [Abstract][Full Text] [Related]
11. Immune checkpoint inhibitors in malignancies after liver transplantation: A systematic review and pooled analysis.
Kayali S; Pasta A; Plaz Torres MC; Jaffe A; Strazzabosco M; Marenco S; Giannini EG
Liver Int; 2023 Jan; 43(1):8-17. PubMed ID: 36102312
[TBL] [Abstract][Full Text] [Related]
12. Immune Checkpoint Inhibitors in Solid Organ Transplant Recipients With Advanced Skin Cancers-Emerging Strategies for Clinical Management.
Ferrándiz-Pulido C; Leiter U; Harwood C; Proby CM; Guthoff M; Scheel CH; Westhoff TH; Bouwes Bavinck JN; Meyer T; Nägeli MC; Del Marmol V; Lebbé C; Geusau A
Transplantation; 2023 Jul; 107(7):1452-1462. PubMed ID: 36706163
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy for hepatocellular carcinoma recurrence after liver transplantation, can we harness the power of immune checkpoint inhibitors?
Jiang J; Huang H; Chen R; Lin Y; Ling Q
Front Immunol; 2023; 14():1092401. PubMed ID: 36875077
[TBL] [Abstract][Full Text] [Related]
14. The Role of Immunotherapy in Hepatocellular Carcinoma: A Systematic Review and Pooled Analysis of 2,402 Patients.
Ziogas IA; Evangeliou AP; Giannis D; Hayat MH; Mylonas KS; Tohme S; Geller DA; Elias N; Goyal L; Tsoulfas G
Oncologist; 2021 Jun; 26(6):e1036-e1049. PubMed ID: 33314549
[TBL] [Abstract][Full Text] [Related]
15. Stable liver graft post anti-PD1 therapy as a bridge to transplantation in an adolescent with hepatocellular carcinoma.
Kang E; Martinez M; Moisander-Joyce H; Saenger YM; Griesemer AD; Kato T; Yamashiro DJ; Remotti H; Gartrell RD
Pediatr Transplant; 2022 May; 26(3):e14209. PubMed ID: 34907641
[TBL] [Abstract][Full Text] [Related]
16. Preoperative Immunotherapy in Hepatocellular Carcinoma: Current State of the Art.
Laschtowitz A; Roderburg C; Tacke F; Mohr R
J Hepatocell Carcinoma; 2023; 10():181-191. PubMed ID: 36789252
[TBL] [Abstract][Full Text] [Related]
17. Immune Checkpoint Inhibitors as Therapy to Down-Stage Hepatocellular Carcinoma Prior to Liver Transplantation.
Katariya NN; Lizaola-Mayo BC; Chascsa DM; Giorgakis E; Aqel BA; Moss AA; Uson Junior PLS; Borad MJ; Mathur AK
Cancers (Basel); 2022 Apr; 14(9):. PubMed ID: 35565184
[TBL] [Abstract][Full Text] [Related]
18. An analysis report on the application of immune checkpoint inhibitors after liver transplantation.
Xie M; Dang ZP; Sun XG; Zhang B; Zhang Q; Tian QJ; Cai JZ; Rao W
Ther Adv Chronic Dis; 2022; 13():20406223221099334. PubMed ID: 35620187
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy before liver transplant in unresectable hepatocellular carcinoma: a case report.
Ohm H; Khwaja R; Karachiwala H
J Gastrointest Oncol; 2023 Dec; 14(6):2644-2649. PubMed ID: 38196545
[TBL] [Abstract][Full Text] [Related]
20. Clinical outcomes of solid organ transplant recipients with metastatic cancers who are treated with immune checkpoint inhibitors: A single-center analysis.
Owoyemi I; Vaughan LE; Costello CM; Thongprayoon C; Markovic SN; Herrmann J; Otley CC; Taner T; Mangold AR; Leung N; Herrmann SM; Kukla A
Cancer; 2020 Nov; 126(21):4780-4787. PubMed ID: 32786022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]